• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603676.SS
Share

Tibet Weixinkang Medicine Co., Ltd. Stocks

CN¥ 9.24Last Updated 15.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 562.58M

CN¥ 9.24
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Tibet Weixinkang Medicine Co., Ltd., a pharmaceutical enterprise headquartered in Lhasa, China, is dedicated to the entire lifecycle of medicinal products within the country, encompassing their research and development, manufacturing, and sales. The company's diverse range of offerings includes specialized vitamins for parenteral nutrition, electrolyte solutions, intravenous iron preparations, antibiotic medications, and therapies designed for digestive system and liver conditions. Among its specific injectable products are multivitamins, potassium magnesium aspartate, iron sucrose, and potassium aspartate. Established in 2006, the firm operated under the name Weixinkang Medicine Youxian Gongsi until its rebranding to Tibet Weixinkang Medicine Co., Ltd. occurred in 2015.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 11:30

Strive has been paying dividends every day for a month now. What risks does the company face?

16.07.2026 10:45

Samsung and SK Hynix shares plummeted ahead of TSMC's earnings report. The market is waiting for signals regarding AI

16.07.2026 10:30

Morning Roundup: New Strikes on Iran, Anthropic Heads Toward an IPO, and a Sell-Off in Asia

16.07.2026 09:30

"Market Leaders Face a Test of Resilience": Goldman Explains How to Protect Your Portfolio

16.07.2026 08:30

United Warned of $6 Billion in Additional Fuel Costs. Why the Profit Forecast Was Raised

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026